Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer

Future Oncology
Siddharth Sheth, Jared Weiss

Abstract

Until recently, palliative options for the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have been cytotoxic chemotherapy and EGFR inhibitors. These agents offer limited efficacy with substantial toxicity. The development of novel immune checkpoint inhibitors has challenged the standard treatment. Pembrolizumab is a potent and highly selective humanized monoclonal antibody that blocks the interaction between PD-1, an immune checkpoint receptor and its ligands PD-L1 and -2. In August 2016, the US FDA approved the use of pembrolizumab in R/M HNSCC following disease progression on or after platinum-containing chemotherapy. This review highlights the pharmacology, therapeutic efficacy and tolerability data relevant to the use of pembrolizumab for the treatment of R/M HNSCC. Readers will gain greater insight into the HNSCC tumor microenvironment, available biomarkers, and learn about important clinical considerations associated with the use of pembrolizumab and similar immune checkpoint inhibitors.

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C JacobsL Schacter
Jan 13, 1983·The New England Journal of Medicine·W K Hong, R Bromer
Mar 22, 1996·Science·D R LeachJ P Allison
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Dec 21, 2004·International Journal of Cancer. Journal International Du Cancer·André Lopes CarvalhoLuiz Paulo Kowalski
Apr 9, 2005·Current Opinion in Oncology·Dirk Schrijvers, Jan B Vermorken
Apr 23, 2005·British Journal of Cancer·T Y Seiwert, E E W Cohen
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael K GibsonUNKNOWN Eastern Cooperative Oncology Group
Jun 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Dimitrios Colevas
Apr 3, 2008·Mayo Clinic Proceedings·Shanthi Marur, Arlene A Forastiere
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Oct 30, 2009·Acta Oto-laryngologica·Juan José GrauJose Luís Blanch
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V GrégoireUNKNOWN EHNS-ESMO-ESTRO Guidelines Working Group
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jan 10, 2013·Current Opinion in Immunology·Joel CrespoWeiping Zou
Jun 15, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T Y SeiwertE E W Cohen
Jul 25, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tanguy Y SeiwertPeter S Hammerman
Dec 3, 2014·Trends in Molecular Medicine·Kim C OhaegbulamXingxing Zang
Jan 30, 2015·Nature·UNKNOWN Cancer Genome Atlas Network
May 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amita PatnaikAnthony W Tolcher
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Aug 12, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Victoria L Chiou, Mauricio Burotto
Jan 15, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M MichotO Lambotte
Mar 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F Stephen HodiJedd D Wolchok
Aug 4, 2016·Expert Opinion on Drug Metabolism & Toxicology·Teresa C Longoria, Krishnansu S Tewari
Sep 21, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M ChowTanguy Y Seiwert
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Oct 26, 2016·JCI Insight·Rajarsi MandalLuc Gt Morris
Nov 9, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stéphane ChampiatCharles Ferté
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Mar 9, 2017·The Lancet Oncology·Lesley SeymourUNKNOWN RECIST working group
Mar 23, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joshua BaumlRobert Haddad
Mar 30, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shumei KatoRazelle Kurzrock
Apr 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Saâda-BouzidC Le Tourneau
May 19, 2017·Journal for Immunotherapy of Cancer·Tomoko FreshwaterJulie A Stone
Jun 18, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer H YearleyTerrill McClanahan
Jun 27, 2017·The Journal of Clinical Investigation·Mark AyersTerrill K McClanahan
Sep 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T Y SeiwertE E W Cohen

❮ Previous
Next ❯

Citations

Feb 13, 2019·Expert Opinion on Investigational Drugs·Ana Marija SolaJennifer R Grandis

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay

Clinical Trials Mentioned

NCT02358031
NCT02718820
NCT02575404
NCT02318771
NCT03245489
NCT02521870
NCT02626000
NCT02538510
NCT03049618
NCT02255097

Software Mentioned

iRECIST

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.